|
| Status |
Public on Aug 18, 2015 |
| Title |
MDA_FFPE125 |
| Sample type |
RNA |
| |
|
| Source name |
BLADDER
|
| Organism |
Homo sapiens |
| Characteristics |
sample procured: surgery
treatment: DDMVAC and bevacizumab
pretreatment sample record-pair: GSM1173974
subtype (tur_surgery)1-basal;2-p53 like;3-luminal: 2
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA from FFPE was extracted by High Pure miRNA Isolation Kit (Roche). Quality control was performed by NanoDrop ND-1000.
|
| Label |
whole genome DASL
|
| Label protocol |
Standard Illuminal whole genome DASL method
|
| |
|
| Hybridization protocol |
Standard Illumina whole genome DASL hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Data processing |
Quantile normalization in the Linear Models for Microarray Data (LIMMA) package in the R language environment was used to normalize the data
|
| |
|
| Submission date |
Jun 11, 2015 |
| Last update date |
Aug 18, 2015 |
| Contact name |
Woonyoung Choi |
| Organization name |
Md Anderson Cancer center
|
| Street address |
1515 Holcombe
|
| City |
Houston |
| State/province |
TX |
| ZIP/Postal code |
77030 |
| Country |
USA |
| |
|
| Platform ID |
GPL14951 |
| Series (1) |
| GSE69795 |
a phase 2 trial of DDMVAC and bevacizumab in urothelial cancer |
|
